{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:26:56Z","timestamp":1761863216562,"version":"3.44.0"},"reference-count":48,"publisher":"BMJ","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Heart"],"accepted":{"date-parts":[[2013,2,12]]},"published-print":{"date-parts":[[2013,9,1]]},"abstract":"<jats:p>Conventional drug eluting stents allow predictable long-term relief from coronary obstruction in most cases. However, rigid permanent metallic stents alter flow dynamics, abolish vascular reactivity, limit the potential for maximal vasodilation and promote ongoing inflammation and abnormalities of endothelial function. It is hypothesised that they may contribute to mal-apposition of stent struts, accelerated atheroma within the stented segment and perhaps very late stent thrombosis. Dramatic advances in bioabsorbable materials and technology have delivered the potential for a fully absorbable scaffold, which is able to mechanically support the coronary artery, and elute a drug, for a predetermined time period and is then fully absorbed in to the vascular wall. This could permit the \u2018normalisation\u2019 of vascular function, with a number of potential advantages including true normalisation of vasomotor function, restoration of physiological responses to stress\/exercise and completion of the vascular response to stenting, without the long-term consequences related to inflammation, accelerated atherosclerosis and thrombosis. Currently, over 16 different scaffolds are at varying stages of development. This review summarises the rationale for the development of absorbable scaffolds and the principal clinical research data.<\/jats:p>","DOI":"10.1136\/heartjnl-2012-303346","type":"journal-article","created":{"date-parts":[[2013,3,8]],"date-time":"2013-03-08T21:10:55Z","timestamp":1362777055000},"page":"1236-1243","source":"Crossref","is-referenced-by-count":23,"title":["Bioabsorbable scaffolds for the treatment of obstructive coronary artery disease: the next revolution in coronary intervention?"],"prefix":"10.1136","volume":"99","author":[{"given":"Niket","family":"Patel","sequence":"first","affiliation":[{"name":"Cardiology Department, John Radcliffe Hospital, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian P","family":"Banning","sequence":"additional","affiliation":[{"name":"Cardiology Department, John Radcliffe Hospital, Oxford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,3,8]]},"reference":[{"key":"2025092007083372000_99.17.1236.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61444-5"},{"key":"2025092007083372000_99.17.1236.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9290(00)00066-X"},{"key":"2025092007083372000_99.17.1236.3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000016360.97819.44"},{"key":"2025092007083372000_99.17.1236.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.04.030"},{"key":"2025092007083372000_99.17.1236.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.730010"},{"key":"2025092007083372000_99.17.1236.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61672-3"},{"key":"2025092007083372000_99.17.1236.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.06.008"},{"key":"2025092007083372000_99.17.1236.8","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA18"},{"key":"2025092007083372000_99.17.1236.9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.103911"},{"key":"2025092007083372000_99.17.1236.10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.109.859173"},{"key":"2025092007083372000_99.17.1236.11","first-page":"537","article-title":"Biodegradable stents and non-biodegradable stents","volume":"57","author":"Garg","year":"2009","journal-title":"Minerva Cardioangiol"},{"key":"2025092007083372000_99.17.1236.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.07.006"},{"key":"2025092007083372000_99.17.1236.13","doi-asserted-by":"publisher","DOI":"10.1586\/erc.09.138"},{"key":"2025092007083372000_99.17.1236.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60324-9"},{"key":"2025092007083372000_99.17.1236.15","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA17"},{"key":"2025092007083372000_99.17.1236.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.01.011"},{"key":"2025092007083372000_99.17.1236.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.803528"},{"key":"2025092007083372000_99.17.1236.18","first-page":"286","article-title":"A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: The SPIRIT II trial","volume":"2","author":"Serruys","year":"2006","journal-title":"EuroIntervention"},{"key":"2025092007083372000_99.17.1236.19","first-page":"266","article-title":"One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowing (The SPIRIT FIRST Trial)","volume":"1","author":"Tsuchida","year":"2005","journal-title":"EuroIntervention"},{"key":"2025092007083372000_99.17.1236.20","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000156462.97532.8F"},{"key":"2025092007083372000_99.17.1236.21","doi-asserted-by":"crossref","first-page":"139823","DOI":"10.5402\/2012\/139823","article-title":"CT imaging of coronary stents: past, present, and future","volume":"2012","author":"Mahnken","year":"2012","journal-title":"ISRN Cardiol"},{"key":"2025092007083372000_99.17.1236.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-007-2995-y"},{"key":"2025092007083372000_99.17.1236.23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.000901"},{"key":"2025092007083372000_99.17.1236.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.4.399"},{"key":"2025092007083372000_99.17.1236.25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60853-8"},{"key":"2025092007083372000_99.17.1236.26","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(12)60204-6"},{"issue":"Suppl N","key":"2025092007083372000_99.17.1236.27","first-page":"N215","article-title":"Twelve-month clinical and angiographic results of the multicenter first-in-man BIOSOLVE-1 study with the paclitaxel-eluding bioabsorbable magnesium scaffold","volume":"8","author":"Haude","year":"2012","journal-title":"EuroIntervention"},{"key":"2025092007083372000_99.17.1236.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60415-8"},{"issue":"Suppl N","key":"2025092007083372000_99.17.1236.29","first-page":"N216","article-title":"Six and twelve-month greyscale and virtual histology IVUS results with the drug eluting absorbable metal scaffold in the BIOSOLVE-I study","volume":"8","author":"Koolen","year":"2012","journal-title":"EuroIntervention"},{"key":"2025092007083372000_99.17.1236.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2008.09.015"},{"key":"2025092007083372000_99.17.1236.31","doi-asserted-by":"crossref","unstructured":"Haude M Erbel R Erne P . Two-Year Clinical Data of Cohort 1 and Multi-modality Imaging Results up to 1-Year Follow-up of the BIOSOLVE-I Study with the Paclitaxel- Eluting Bioabsorbable Magnesium Scaffold (DREAMS). Presented at: TCT October 2012.","DOI":"10.1016\/j.jacc.2012.08.046"},{"key":"2025092007083372000_99.17.1236.32","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA13"},{"key":"2025092007083372000_99.17.1236.33","doi-asserted-by":"crossref","unstructured":"Verheye S . Multicenter First-in-Man Evaluation of the Myolimus-Eluting Bioresorbable Coronary Scaffold: 6-month Imaging and 12-month Clinical Results. Presented at: TCT October 2012.","DOI":"10.1161\/circ.126.suppl_21.A18819"},{"key":"2025092007083372000_99.17.1236.34","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA9"},{"key":"2025092007083372000_99.17.1236.35","unstructured":"Grube E . Bioabsorbable stent. The Boston Scientific and REVA technology. Presented at euroPCR 2009."},{"key":"2025092007083372000_99.17.1236.36","unstructured":"Costa RA . REVA ReZolve Clinical Program Update. Presented at: TCT October 2012."},{"key":"2025092007083372000_99.17.1236.37","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.21607"},{"key":"2025092007083372000_99.17.1236.38","unstructured":"Jabara R . Poly-anhydride based on salicylic acid and adipic acid anhydride. Presented at: EuroPCR 2009 ."},{"key":"2025092007083372000_99.17.1236.39","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV7I9A168"},{"issue":"Suppl B","key":"2025092007083372000_99.17.1236.40","doi-asserted-by":"crossref","first-page":"B11","DOI":"10.1016\/j.jacc.2012.08.045","article-title":"TCT-37 five-year clinical outcomes and non-invasive angiographic imaging results with functional assessment after bioresorbable everolimus-eluting scaffold implantation in patients with de novo coronary artery disease","volume":"60","author":"Onuma","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2025092007083372000_99.17.1236.41","doi-asserted-by":"crossref","first-page":"932","DOI":"10.4244\/EIJV5I8A157","article-title":"In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial","volume":"5","author":"Okamura","year":"2010","journal-title":"EuroIntervention"},{"key":"2025092007083372000_99.17.1236.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2011.05.050"},{"key":"2025092007083372000_99.17.1236.43","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(12)60320-9"},{"key":"2025092007083372000_99.17.1236.44","unstructured":"Banning A . ABSORB clinical programme- the latest! Presented at: euroPCR 2012."},{"key":"2025092007083372000_99.17.1236.45","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr466"},{"key":"2025092007083372000_99.17.1236.46","unstructured":"Bartorelli AL . ABSORB EXTEND: An Interim Report on the 6-month clinical outcome from the first 500 patients registered. Presented at TCT 2012."},{"key":"2025092007083372000_99.17.1236.47","doi-asserted-by":"crossref","unstructured":"Bartorelli AL . ABSORB EXTEND: An Interim Report on the 12-Month Clinical Outcomes from the First 250 Patients Registered. Presented at TCT 2012.","DOI":"10.1016\/j.jacc.2012.08.042"},{"key":"2025092007083372000_99.17.1236.48","doi-asserted-by":"publisher","DOI":"10.4244\/EIJV5IFA11"}],"container-title":["Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/heartjnl-2012-303346","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T14:08:43Z","timestamp":1758377323000},"score":1,"resource":{"primary":{"URL":"https:\/\/heart.bmj.com\/lookup\/doi\/10.1136\/heartjnl-2012-303346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,8]]},"references-count":48,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2013,8,2]]},"published-print":{"date-parts":[[2013,9,1]]}},"alternative-id":["10.1136\/heartjnl-2012-303346"],"URL":"https:\/\/doi.org\/10.1136\/heartjnl-2012-303346","relation":{},"ISSN":["1355-6037","1468-201X"],"issn-type":[{"type":"print","value":"1355-6037"},{"type":"electronic","value":"1468-201X"}],"subject":[],"published":{"date-parts":[[2013,3,8]]}}}